<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-EOH-2286</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2286</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МАТЕРИАЛЫ ФОРУМА "ДНИ ИММУНОЛОГИИ В СПБ" 2021</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ РЕАКТИВАЦИИ ВИРУСОВ ГЕРПЕСА ЧЕЛОВЕКА НА СИСТЕМНУЮ ПРОДУКЦИЮ ЦИТОКИНОВ У ПАЦИЕНТОВ С БОЛЕЗНЬЮ БЕХЧЕТА И УВЕИТАМИ</article-title><trans-title-group xml:lang="en"><trans-title>EFFECT OF HUMAN HERPES VIRUS REACTIVATION ON SYSTEMIC CYTOKINE PRODUCTION IN PATIENTS WITH BEHCET’S DISEASE AND UVEITIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кричевская</surname><given-names>Г. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Krichevskaya</surname><given-names>G. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., ведущий научный сотрудник отдела иммунологии и вирусологии,</p><p>105062, Москва, ул. Садовая-Черногрязская, 14/19</p></bio><bio xml:lang="en"><p>PhD (Medicine), Leading Research Associate, Department of Immunology and Virology,</p><p>105062, Moscow, Sadovaya-Chernogryazskaya str., 14/19</p></bio><email xlink:type="simple">skai6@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сорожкина</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sorozhkina</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник,</p><p>105062, Москва, ул. Садовая-Черногрязская, 14/19</p></bio><bio xml:lang="en"><p>Research Associate,</p><p>105062, Moscow, Sadovaya-Chernogryazskaya str., 14/19</p></bio><email xlink:type="simple">skai6@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балацкая</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Balatskaya</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.б.н., начальник отдела иммунологии и вирусологии,</p><p>105062, Москва, ул. Садовая-Черногрязская, 14/19</p></bio><bio xml:lang="en"><p>PhD (Biology), Head, Department of Immunology and Virology,</p><p>105062, Moscow, Sadovaya-Chernogryazskaya str., 14/19</p></bio><email xlink:type="simple">skai6@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куликова</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulikova</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>старший научный сотрудник отдела иммунологии и вирусологии,</p><p>105062, Москва, ул. Садовая-Черногрязская, 14/19</p></bio><bio xml:lang="en"><p>Senior Research Associate, Department of Immunology and Virology,</p><p>105062, Moscow, Sadovaya-Chernogryazskaya str., 14/19</p></bio><email xlink:type="simple">skai6@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андрюшин</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Andryushin</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник отдела иммунологии и вирусологии,</p><p>105062, Москва, ул. Садовая-Черногрязская, 14/19</p></bio><bio xml:lang="en"><p>Research Associate, Department of Immunology and Virology,</p><p>105062, Moscow, Sadovaya-Chernogryazskaya str., 14/19</p></bio><email xlink:type="simple">skai6@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдова</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Davidova</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., врач-офтальмолог, научный сотрудник отдела патологии сетчатки,</p><p>105062, Москва, ул. Садовая-Черногрязская, 14/19</p></bio><bio xml:lang="en"><p>PhD (Medicine), Ophthalmologist, Research Associate, Department of Retina and Optic Nerve Pathology, </p><p>105062, Moscow, Sadovaya-Chernogryazskaya str., 14/19</p></bio><email xlink:type="simple">skai6@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лисицына</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lisitsyna</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., ведущий научный сотрудник лаборатории сосудистой ревматологии,</p><p>Москва</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Leading Research Associate, </p><p>Moscow</p></bio><email xlink:type="simple">skai6@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>08</day><month>10</month><year>2021</year></pub-date><volume>23</volume><issue>4</issue><fpage>767</fpage><lpage>774</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кричевская Г.И., Сорожкина Е.С., Балацкая Н.В., Куликова И.Г., Андрюшин А.Е., Давыдова Г.А., Лисицына Т.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Кричевская Г.И., Сорожкина Е.С., Балацкая Н.В., Куликова И.Г., Андрюшин А.Е., Давыдова Г.А., Лисицына Т.А.</copyright-holder><copyright-holder xml:lang="en">Krichevskaya G.I., Sorozhkina E.S., Balatskaya N.V., Kulikova I.G., Andryushin A.E., Davidova G.A., Lisitsyna T.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2286">https://www.mimmun.ru/mimmun/article/view/2286</self-uri><abstract><p>Болезнь Бехчета (ББ) – системное аутовоспалительно-аутоиммунное заболевание (хронический системный васкулит) невыясненной этиологии, увеит развивается почти у 70% пациентов. Патогенез ББ сложен, среди инфекционных триггерных факторов важную роль играют герпесвирусы человека (HHV). Известна способность HHV модулировать продукцию цитокинов и уклоняться от иммунного ответа организма.</p><p>Цель работы: определить влияние Herpes simplex virus type 1 (HSV-1), Herpes simplex virus type 2 (HSV-2), Cytomegalovirus (CMV), Epstein-Barr virus (EBV) на системные уровни хемокинов, про- и противовоспалительных цитокинов при ББ с симптомами увеитов и без. Сыворотки 116 пациентов с ББ, хронически инфицированных герпесвирусами, исследовали в иммуноферментном анализе на наличие IgG-антител к предранним антигенам HSV-1,2 и раннему антигену EBV (маркеров реактивации ННV). Концентрацию IL-1β, IFNγ, MCP-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12p70, IL-13, IL-18, TNFα, GM-CSF, Eotaxin, GRO-α, IP-10, MIP-1α, MIP-1β, SDF-1α, RANTES определяли в мультиплексном анализе, TGF-β1, TGF-β2 – в иммуноферментном анализе. В зависимости от наличия и активности увеита выделили 3 группы пациентов с ББ: 1-я группа – активный увеит, 2-я группа – увеит в ремиссии, 3-я группа – ББ без поражения глаз. По результатам серологического анализа в каждой группе выделили 2 подгруппы: а) пациенты с наличием антител-маркеров реактивации хотя бы одного из исследованных HHV, б) пациенты, хронически инфицированные HHV, без признаков реактивации. Средний уровень и частоту выявления цитокинов и хемокинов у пациентов с активными увеитами (1а, 1б) и в стадии ремиссии (2а, 2б) сравнивали с результатами обследования пациентов без поражения глаз (3а, 3б), сопоставляли подгруппы с хронической ВГЧинфекцией (подгруппа «б») и ее реактивацией (подгруппа «а»).</p><p>Достоверное повышение сывороточного содержания хемокинов MCP-1/ССL2, MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5), IP-10, SDF-1α, а также IFNγ, TGF-β1 и TGF-β2 отмечено у пациентов с увеитами (независимо от их активности) и маркерами реактивации HHV по сравнению с пациентами без увеитов.</p><p>Полученные данные указывают на возможное влияние реактивации хронических герпесвирусных инфекций на системную продукцию цитокинов и хемокинов у пациентов с ББ и увеитами, причем наибольшие изменения касаются хемокинов. </p></abstract><trans-abstract xml:lang="en"><p>Behcet’s disease (BD) is a systemic autoinflammatory-autoimmune disease (chronic systemic vasculitis) of unknown etiology, almost 70% of patients develop uveitis. BD pathogenesis is complex, human herpesviruses (HHV) play an important role among infectious trigger factors. Ability of herpesviruses to modulate cytokine production and evade host’s immune response is known.</p><p>Aim of the study was to assess the effect of Herpes simplex virus type 1, Herpes simplex virus type 2, Cytomegalovirus, Epstein-Barr virus on systemic levels of chemokines, pro- and anti-inflammatory cytokines in BD with and without uveitis. Serum samples were collected from 116 BD patients chronically infected with HHV and examined in ELISA-test for markers of HHV reactivation (IgG-antibodies to immediate early HSV antigens 1, 2 and CMV, early EBV antigen). Concentration of IL-1β, IFNγ, MCP-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12p70, IL-13, IL-18, TNFα, GMCSF, Eotaxin, GRO-α, IP-10, MIP-1α, MIP-1β, SDF-1α, RANTES detected in multiplex analysis. TGF-β1, TGF-β2 were measured in ELISA-test. Depending on presence and activity of uveitis 3 groups of patients with BD were identified: group 1 – active uveitis, group 2 – remission of uveitis, group 3 – BD without ocular manifestations. After serological study 2 subgroups were highlighted in each group: a) patients with antibody markers of reactivation of at least one HHV, b) patients chronically infected with HHV, without serological signs of reactivation. Mean level and detection rate of cytokines and chemokines in patients with active uveitis (1a, 1b) and in remission (2a, 2b) were compared with patients without eye damage (3a, 3b). Chronic HHV infection (subgroup “b”) was compared with reactivation (subgroup “a”). A significant increase of MCP-1/ CCL2, MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5, IP-10, SDF-1α chemokines in serum, as well as IFNγ, TGF-β1, and TGF-β2 was observed in patients with uveitis (regardless of their activity) and HHV reactivation compared to patients without uveitis. Our data indicate that systemic production of cytokines and chemokines in BD patients and uveitis could be affected by the activity of chronic herpesvirus infections, and the greatest changes are related to chemokines. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Бехчета</kwd><kwd>вирусы герпеса человека</kwd><kwd>цитокины</kwd><kwd>хемокины</kwd><kwd>увеит</kwd><kwd>реактивация ВГЧ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Behcet’s disease</kwd><kwd>human herpes viruses</kwd><kwd>cytokines</kwd><kwd>hemokines</kwd><kwd>uveitis</kwd><kwd>HHV reactivation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Abu El-Asrar A.M., Berghmans N., Al-Obeidan S.A., Gikandi P.W., Opdenakker G., van Damme J., Struyf S. The CC chemokines CCL8, CCL13 and CCL20 are local inflammatory biomarkers of HLA-B27-associated uveitis. Acta Ophthalmol., 2019, Vol. 97, no. 1, pp. e122-e128.</mixed-citation><mixed-citation xml:lang="en">Abu El-Asrar A.M., Berghmans N., Al-Obeidan S.A., Gikandi P.W., Opdenakker G., van Damme J., Struyf S. The CC chemokines CCL8, CCL13 and CCL20 are local inflammatory biomarkers of HLA-B27-associated uveitis. Acta Ophthalmol., 2019, Vol. 97, no. 1, pp. e122-e128.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Belguendous H.,Messaoudene D., Lahmar-Belguendouz K., Djeraba Z., Otmani F., Terahi M., Tiar M., Hartani D., Lahlou-Boukoffa O.S., Touil-Boukoffa C. In vivo and in vitro IL-18 production during uveitis associated with Behçet disease: effect of glucocorticoid therapy. J. Fr. Ophtalmol., 2015, Vol. 38, no. 3, pp. 206-212.</mixed-citation><mixed-citation xml:lang="en">Belguendous H.,Messaoudene D., Lahmar-Belguendouz K., Djeraba Z., Otmani F., Terahi M., Tiar M., Hartani D., Lahlou-Boukoffa O.S., Touil-Boukoffa C. In vivo and in vitro IL-18 production during uveitis associated with Behçet disease: effect of glucocorticoid therapy. J. Fr. Ophtalmol., 2015, Vol. 38, no. 3, pp. 206-212.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ksiaa I., Abroug N., Kechida M., Zina S., Jelliti B., Khochtali S., Attia S., Khairallah M. Eye and Behçet’s disease. J. Fr. Ophtalmol., 2019, Vol. 42, no. 4, pp. e133-e146.</mixed-citation><mixed-citation xml:lang="en">Ksiaa I., Abroug N., Kechida M., Zina S., Jelliti B., Khochtali S., Attia S., Khairallah M. Eye and Behçet’s disease. J. Fr. Ophtalmol., 2019, Vol. 42, no. 4, pp. e133-e146.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Leccese P., Alpsoy E. Behçet’s disease: an overview of etiopathogenesis. Front. Immunol., 2019, Vol. 10, 1067. doi: 10.3389/fimmu.2019.01067.</mixed-citation><mixed-citation xml:lang="en">Leccese P., Alpsoy E. Behçet’s disease: an overview of etiopathogenesis. Front. Immunol., 2019, Vol. 10, 1067. doi: 10.3389/fimmu.2019.01067.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lisitsyna T.A., Alekberova Z.S., Goloeva R.G., Davydova G.A. Behcet’s disease: clinical manifestations, current principles of diagnosis and therapy. Rheumatology Science and Practice, 2019, Vol. 57, no. 5, pp. 553-563. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Lisitsyna T.A., Alekberova Z.S., Goloeva R.G., Davydova G.A. Behcet’s disease: clinical manifestations, current principles of diagnosis and therapy. Rheumatology Science and Practice, 2019, Vol. 57, no. 5, pp. 553-563. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mesquida M., Molins B., Llorenç V., Sainz de la Maza M., Hernandez M.V., Espinosa G., Adán A. Proinflammatory cytokines and C-reactive protein in uveitis associated with Behçet’s disease. Mediators Inflamm., 2014, Vol. 2014, 396204. doi: 10.1155/2014/396204.</mixed-citation><mixed-citation xml:lang="en">Mesquida M., Molins B., Llorenç V., Sainz de la Maza M., Hernandez M.V., Espinosa G., Adán A. Proinflammatory cytokines and C-reactive protein in uveitis associated with Behçet’s disease. Mediators Inflamm., 2014, Vol. 2014, 396204. doi: 10.1155/2014/396204.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Moskalev A.V., Rudoy A.S., Apchel A.V., Zueva V.O., Kazimova O.E. Features of biology of transforming growth factor β and immunopathology. Bulletin of Russian Military Medical Academy, 2016, Vol. 2, no. 54, pp. 206-216. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Moskalev A.V., Rudoy A.S., Apchel A.V., Zueva V.O., Kazimova O.E. Features of biology of transforming growth factor β and immunopathology. Bulletin of Russian Military Medical Academy, 2016, Vol. 2, no. 54, pp. 206-216. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Petrovskaya M.S., Krichevskaya G.I., Denisova E.V., Katargina L.A., Kulikova I.G. Importance of Epstein– Barr virus infection in pathogenesis of proliferative complications in children with endogenous uveitis. Russian Journal of Infection and Immunity, 2019, Vol. 9, no. 5-6, pp. 800-804. (In Russ.) doi: 10.15789/2220-7619-2019-5-6- 800-804.</mixed-citation><mixed-citation xml:lang="en">Petrovskaya M.S., Krichevskaya G.I., Denisova E.V., Katargina L.A., Kulikova I.G. Importance of Epstein– Barr virus infection in pathogenesis of proliferative complications in children with endogenous uveitis. Russian Journal of Infection and Immunity, 2019, Vol. 9, no. 5-6, pp. 800-804. (In Russ.) doi: 10.15789/2220-7619-2019-5-6- 800-804.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Prokhorova O.V., Olina A.A., Tolibova G.Kh., Tral’ T.G. Stromal cell-derived factor: pathological and clinical potentialities. Russian Journal of Woman and Child Health, 2020, Vol. 3, no. 3, pp. 198-204. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Prokhorova O.V., Olina A.A., Tolibova G.Kh., Tral’ T.G. Stromal cell-derived factor: pathological and clinical potentialities. Russian Journal of Woman and Child Health, 2020, Vol. 3, no. 3, pp. 198-204. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sayeed H.M., Lee E.S., Byun H.O., Sohn S. The role of CCR1 and therapeutic effects of anti-CCL3 antibody in herpes simplex virus-induced Behçet’s disease mouse model. Immunology, 2019, Vol. 158, no. 3, pp. 206-218.</mixed-citation><mixed-citation xml:lang="en">Sayeed H.M., Lee E.S., Byun H.O., Sohn S. The role of CCR1 and therapeutic effects of anti-CCL3 antibody in herpes simplex virus-induced Behçet’s disease mouse model. Immunology, 2019, Vol. 158, no. 3, pp. 206-218.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sorozhkina E.S., Balatskaya N.V., Davidova G.I., Lisitsyna T.A. Cytokine screen in serum of BD patients with eye lesions. Medical Immunology (Russia), 2017, Vol. 19, Special edition, p. 225. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Sorozhkina E.S., Balatskaya N.V., Davidova G.I., Lisitsyna T.A. Cytokine screen in serum of BD patients with eye lesions. Medical Immunology (Russia), 2017, Vol. 19, Special edition, p. 225. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tong B., Liu X., Xiao J., Su G. Immunopathogenesis of Behcet’s Disease. Front. Immunol., 2019, Vol. 10, 665. doi: 10.3389/fimmu.2019.00665.</mixed-citation><mixed-citation xml:lang="en">Tong B., Liu X., Xiao J., Su G. Immunopathogenesis of Behcet’s Disease. Front. Immunol., 2019, Vol. 10, 665. doi: 10.3389/fimmu.2019.00665.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Z.Y., Chen S.L., Shen N., Lu Y. Cytokines and Behcet’s disease. Autoimmun. Rev., 2012 ,Vol. 11, no. 10, pp. 699-704.</mixed-citation><mixed-citation xml:lang="en">Zhou Z.Y., Chen S.L., Shen N., Lu Y. Cytokines and Behcet’s disease. Autoimmun. Rev., 2012 ,Vol. 11, no. 10, pp. 699-704.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y., Qiu, Y., Yu H., Yi S., Su W., Kijlstra A., Yang P. Aberrant DNA methylation of GATA binding protein 3 (GATA3), interleukin-4 (IL-4), and transforming growth factor-β (TGF-β) promoters in Behcet’s disease. Oncotarget, 2017, Vol. 8, no. 38, pp. 64263-64272.</mixed-citation><mixed-citation xml:lang="en">Zhu Y., Qiu, Y., Yu H., Yi S., Su W., Kijlstra A., Yang P. Aberrant DNA methylation of GATA binding protein 3 (GATA3), interleukin-4 (IL-4), and transforming growth factor-β (TGF-β) promoters in Behcet’s disease. Oncotarget, 2017, Vol. 8, no. 38, pp. 64263-64272.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
